scholarly journals RELATIONSHIP OF THE PSORIATIC ARTHRITIS IMPACT OF DISEASE SCORE (PsAID-12) WITH RADIOLOGICAL DAMAGE AND DELAY IN THE DIAGNOSIS OF PSORIATIC ARTHRITIS: A MULTICENTER STUDY

2021 ◽  
Author(s):  
Elziane da Cruz Ribeiro e Souza ◽  
Sueli Coelho da Silva Carneiro ◽  
Michel Alexandre Yazbek ◽  
Rita de Cássia Menin ◽  
Roberto Ranza ◽  
...  
2015 ◽  
Vol 93 (0) ◽  
pp. 33-35 ◽  
Author(s):  
I. Olivieri ◽  
S. D'Angelo ◽  
M. Gilio ◽  
C. Palazzi ◽  
E. Lubrano ◽  
...  

2021 ◽  
pp. jrheum.201204
Author(s):  
Eva Galíndez-Agirregoikoa ◽  
Diana Prieto-Peña ◽  
José Luis Martín-Varillas ◽  
Beatriz Joven ◽  
Olga Rusinovich ◽  
...  

Objective Tofacitinib (TOFA) is the first Janus kinase (JAK) inhibitor approved for Psoriatic Arthritis (PsA). It has shown efficacy in patients refractory to anti-TNFα in Randomized Clinical Trials (RCT). Our aim was to assess efficacy and safety of TOFA in clinical practice. Methods Observational, open-label multicenter study of PsA patients treated with TOFA due to inefficacy or adverse events of previous therapies. Outcome variables were efficacy, sparing corticosteroid-dose effect, retention rate and safety. Comparative study of clinical features between our cohort of patients and those from the OPAL BEYOND trial was performed. Results 87 patients (28 women/59 men), mean age of 52.8±11.4 years. All patients were refractory to b-DMARDs and/or to cs-DMARDs plus Apremilast. TOFA was started at 5mg twice daily after a mean follow-up of 12.3±9.3 years from PsA diagnosis. At first month, DAS28ESR decreased from 4.8 [4.1-5.4] to 3.7 [2.8-4.7] (p <0.01), DAPSA from 28 [18.4-34.1] to 15.5 [10.1-25.7] (p < 0.01) and C-reactive protein from 1.9 [0.3-5.0] to 0.5 [0.1-2.2] mg/dL (p < 0.01). Also, TOFA led to a significant reduction of prednisone dose. Mild adverse effects were reported in 21 patients (24.13%), mainly gastrointestinal symptoms. TOFA retention rate at month 6 was 77% (CI 95%; 65.2-86.3 %). Patients of clinical practice were older with longer disease duration and received biologic agents more commonly than those in the OPAL BEYOND trial. Conclusion Data from clinical practice confirm that TOFA seems to be effective, rapid and relatively safe in refractory PsA despite clinical differences with patients in RCT.


2020 ◽  
Vol 20 (7) ◽  
pp. 813-821 ◽  
Author(s):  
Maria Sole Chimenti ◽  
Giulia Lavinia Fonti ◽  
Paola Conigliaro ◽  
Flavia Sunzini ◽  
Rossana Scrivo ◽  
...  

2019 ◽  
Vol 46 (8) ◽  
pp. 904-911 ◽  
Author(s):  
Pierluigi Macchioni ◽  
Carlo Salvarani ◽  
Niccolò Possemato ◽  
Marwin Gutierrez ◽  
Walter Grassi ◽  
...  

Objective.The purpose of the ULISSE study was to evaluate the prevalence of clinical and ultrasonographic (US) entheseal involvement in patients with psoriatic arthritis (PsA), psoriasis, and fibromyalgia syndrome (FMS).Methods.In this cross-sectional multicenter study, patients with PsA and psoriasis (not taking systemic therapy) and FMS underwent a clinical evaluation of the entheses, and a B-mode and power Doppler examination of 6 pairs of entheses.Results.The study analyzed 140 patients with PsA, 51 with psoriasis, and 51 with FMS. Clinical and US examinations were performed in 1960 and 1680 entheses in the PsA group, and 714 and 612 entheses both in the psoriasis group and in the FMS group. In both per-patient and per-enthesis evaluation, the frequency of entheseal tenderness was higher in patients with FMS (92% of the patients and 46% of the entheses, compared with 66%/23% in the PsA group and 59%/18% in the psoriasis group). With US examination, signs of entheseal involvement were more frequent in both the per-patient and per-enthesis evaluation in PsA and psoriasis (about 90% of patients in both the PsA and psoriasis groups and 75% of patients in the FMS group had at least 1 site affected, and 54%, 41%, and 27% of the pairs of entheses in, respectively, PsA, psoriasis, and FMS patients showed at least 1 enthesis involved).Conclusion.The ULISSE study indicated that enthesitis is a common feature in patients with PsA, those with psoriasis, and in those with FMS if only clinical examination is used. US entheseal assessment showed findings more consistent with the 3 disorders.


2014 ◽  
Vol 16 (2) ◽  
pp. 166-176 ◽  
Author(s):  
Satoru Kishi ◽  
Tiago A. Magalhaes ◽  
Richard T. George ◽  
Marc Dewey ◽  
Roger J. Laham ◽  
...  

2013 ◽  
Vol 26 (1) ◽  
pp. 63-70
Author(s):  
Mustafa Akif Sariyildiz ◽  
Ibrahim Batmaz ◽  
Mehmet Guli Çetinçakmak ◽  
Ismail Yıldız ◽  
Kemal Nas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document